ICAM1 and myeloid sarcoma: Although to our knowledge there is no study directly comparing ICAM-1 and VCAM-1 expression levels on the BBB during RRMS, increased levels of the soluble form of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) in the CSF and serum have been reported in MS patients with higher disease activity [81–83].